Allergy Therapeutics (AGY) has provided a trading update for the 6-months to December 2025. 1H26 revenues are expected to be £36.3m (1H25: £34.0m) representing 7% growth on a reported basis, or c3% on a constant currency basis. In our view, this revenue growth is highly encouraging considering the backdrop of the ongoing transition away from unregistered products in Germany and reflects strong growth in the Group’s existing German registered product portfolio. Most notable during the period was ....
